Reported 2 days ago
JonesResearch has downgraded Acrivon Therapeutics (ACRV) from a Buy rating to Hold, citing a need for more data before recommending its shares. The firm is particularly interested in the upcoming results from ACR-2316, expected in the latter half of 2025, to validate the company’s tumor-selection platform.
Source: YAHOO